Novel effective combination chemotherapy using epigenetic modifiers for targeting solid tumors

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K06699
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: Kobe Pharmaceutical University
• Principal Investigator: Hosokawa Mika 神戸薬科大学, 薬学部, 講師 (70548271)
• Co-Investigator(Kenkyū-buntansha): 大河原 賢一 神戸薬科大学, 薬学部, 教授 (30291470)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 低酸素 / エピジェネティック修飾薬 / 固形がん / 併用療法

Outline of Final Research Achievements

Some of epigenetic modifiers was able to improve the effects of anti-cancer drugs attenuated in cancer cells under hypoxia. The suppression of histone methylation induced under hypoxia augmented cancer cell death by anti-cancer drugs. Same as hypoxic conditions, acidic conditions also decreased the effects of anti-cancer drugs in cancer cells although the extent of decrease was smaller in acidic conditions than hypoxic conditions. In addition, some of epigenetic modifiers improved the effects of anti-cancer drugs attenuated in cancer cells under acidic environment.

Free Research Field

生物薬剤学

Academic Significance and Societal Importance of the Research Achievements

固形がんに特有の微小環境を模倣して培養したがん細胞を用いて得られた成果は、抗がん剤治療に耐性を示し有効な治療法のないがんに対する治療法開発に繋がることが期待され、固形がんに対するエピジェネティック修飾薬の臨床応用を進めるための有益な基礎的知見になると考えられる。